ArticleBritish journal of cancer2020

A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.

Christophe Le Tourneau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.